Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Assets (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Current Assets for 7 consecutive years, with $246.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 49.73% year-over-year to $246.5 million, compared with a TTM value of $246.5 million through Sep 2025, down 49.73%, and an annual FY2024 reading of $423.8 million, up 123.36% over the prior year.
  • Current Assets was $246.5 million for Q3 2025 at Summit Therapeutics, down from $309.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $656.7 million in Q4 2022 and bottomed at $79.4 million in Q2 2022.
  • Average Current Assets over 5 years is $243.2 million, with a median of $205.0 million recorded in 2023.
  • The sharpest move saw Current Assets soared 574.85% in 2022, then plummeted 71.11% in 2023.
  • Year by year, Current Assets stood at $97.3 million in 2021, then skyrocketed by 574.85% to $656.7 million in 2022, then tumbled by 71.11% to $189.7 million in 2023, then skyrocketed by 123.36% to $423.8 million in 2024, then tumbled by 41.84% to $246.5 million in 2025.
  • Business Quant data shows Current Assets for SMMT at $246.5 million in Q3 2025, $309.2 million in Q2 2025, and $370.8 million in Q1 2025.